Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Ottervanger JP, et al. Circulation. 2003 Jan 28;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e. Circulation. 2003. PMID: 12551868 Clinical Trial.
Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure.
De Luca G, van 't Hof AW, de Boer MJ, Hoorntje JC, Gosselink AT, Dambrink JH, Ottervanger JP, Zijlstra F, Suryapranata H. De Luca G, et al. Among authors: ottervanger jp. Circulation. 2004 Mar 2;109(8):958-61. doi: 10.1161/01.CIR.0000120504.31457.28. Epub 2004 Feb 23. Circulation. 2004. PMID: 14981008
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML. James SK, et al. Among authors: ottervanger jp. Am J Cardiol. 2006 Jan 15;97(2):167-72. doi: 10.1016/j.amjcard.2005.08.036. Epub 2005 Nov 21. Am J Cardiol. 2006. PMID: 16442356
Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization.
Breeman A, Hordijk-Trion M, Lenzen M, Hoeks S, Ottervanger JP, Bertrand ME, Sechtem U, Zaliunas R, Legrand V, de Boer MJ, Stahle E, Mercado N, Wijns W, Boersma E; Euro Heart Survey on Coronary Revascularization. Breeman A, et al. Among authors: ottervanger jp. J Thorac Cardiovasc Surg. 2006 Nov;132(5):1001-9. doi: 10.1016/j.jtcvs.2006.05.051. J Thorac Cardiovasc Surg. 2006. PMID: 17059915 Free article.
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.
Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL, Westerhout CM, Simes RJ, Granger CB, Zijlstra F; Primary Coronary Angioplasty vs Thrombolysis-2 Trialists Collaborators Group. Timmer JR, et al. Among authors: ottervanger jp. Arch Intern Med. 2007 Jul 9;167(13):1353-9. doi: 10.1001/archinte.167.13.1353. Arch Intern Med. 2007. PMID: 17620527 Clinical Trial.
325 results